Adlai Nortye Acquires Global Rights to Novartis Cancer Drug
publication date: Jul 10, 2018
Adlai Nortye Biopharma, a Hangzhou oncology in-licensing company, acquired global rights to a clinical-stage Novartis cancer drug, buparlisib. Buparlisib is an oral pan-PI3K inhibitor that targets all class 1 PI3K isoforms. Novartis has conducted successful Phase II tests of the drug in various hematologic malignancies and also believes it will show efficacy when paired with paclitaxel in solid tumors. One week ago, Adlai Nortye completed a $53 million Series B financing to develop its portfolio of in-licensed immuno-oncology and oncology candidates. More details....
Stock Symbol: (NYSE: NVS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.